Pfizer
Market cap ₹17,575 Cr
- P/E
- 23.08
- Day range
- ₹3,791.00 – ₹3,858.40
- 52-week range
- ₹3,589.00 – ₹5,257.00
- Volume
- 13,177
- Open
- ₹3,813.90
- Prev close
- ₹3,814.00
Latest results · Q2 FY27(standalone)Revenue ₹727 Cr-41.6%Profit ₹313 Cr-17.7%Margin 43.1%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
PFIZER in NSE indices and F&O
Research profile
Composite 58 / 100Factor percentiles
Derived metrics
- Earn. yield
- 4.3%
- Graham no.
- ₹1,941.14
- vs Graham
- -49.5%
- ROE ÷ P/B
- 4.3%
- 12-1 mom.
- -25.8%
- Return / vol
- -1.05
- Magic Formula
- #99
- Piotroski
- 3/5
- FCF yield
- 5.4%
- PEG
- 0.35
Appears in 13 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| PfizerPFIZER | ₹17,575 Cr | 23.08 | 3.98 | 17.1% | 24.0% | 36.0% | 0.04 | +13.2% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 2d agoHeadlines about Pfizer from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 22.0
- Price / Book
- 4.01
- ROE (FY26)
- 17.1%
- ROCE (latest year)
- 24%
- Dividend yield
- 1.96%
Moving averages (NSE)
- 20-day
- ₹3,782
- Price above
- 50-day
- ₹3,912.62
- Price below
- 200-day
- ₹4,533.42
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 540 | 547 | 563 | 589 | 538 | 592 | 603 | 642 | 645 | 629 | 653 | 727 |
| YoY Sales growth | -13 | -5 | — | — | 0 | — | — | — | — | — | — | — |
| Expenses | 387 | 357 | 385 | 399 | 392 | 364 | 393 | 412 | 417 | 393 | 406 | 466 |
| Operating Profit | 153 | 189 | 177 | 189 | 146 | 228 | 210 | 230 | 228 | 236 | 248 | 261 |
| OPM % | 28% | 35% | 32% | 32% | 27% | 38% | 35% | 36% | 35% | 38% | 38% | 36% |
| Other Income | 44 | 75 | 42 | 43 | 43 | 217 | 67 | 42 | -20 | 50 | 45 | 179 |
| Interest | 3 | 7 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 18 | 14 | 15 | 15 | 15 | 16 | 14 | 14 | 14 | 15 | 14 | 14 |
| Profit before tax | 176 | 244 | 203 | 215 | 172 | 426 | 260 | 255 | 192 | 269 | 277 | 423 |
| Tax % | 26% | 27% | 26% | 26% | 26% | 22% | 26% | 26% | 26% | 26% | 26% | 26% |
| Net Profit | 130 | 179 | 151 | 158 | 128 | 331 | 192 | 189 | 142 | 200 | 204 | 313 |
| EPS in Rs | ₹28.41 | ₹39.10 | ₹32.94 | ₹34.61 | ₹27.89 | ₹72.34 | ₹41.91 | ₹41.32 | ₹31.00 | ₹43.68 | ₹44.70 | ₹68.47 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+8 days since Mar 2021
-4 days since Mar 2021
-41 days since Mar 2021
+45 days since Mar 2021
+6 days since Mar 2021
Strengths, risks & growth
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India. [1] It is the 3rd largest multinational pharmaceutical company in India. [2]
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 58.3%
Risks
- The company has delivered a poor sales growth of 2.39% over past five years.
Compounded Sales Growth
- 10 Years
- +2%
- 5 Years
- +2%
- 3 Years
- +1%
- TTM
- +12%
Compounded Profit Growth
- 10 Years
- +10%
- 5 Years
- +9%
- 3 Years
- +8%
- TTM
- +13%
Stock Price CAGR
- 10 Years
- +8%
- 5 Years
- -6%
- 3 Years
- -1%
- 1 Year
- -25%
Return on Equity
- 10 Years
- +17%
- 5 Years
- +18%
- 3 Years
- +17%
- Last Year
- +18%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 63.92% | 63.92% | 63.92% | 63.92% | 0.00 pp |
| FII | 2.71% | 2.81% | 1.65% | 1.63% | -0.02 pp |
| DII | 17.05% | 16.89% | 17.80% | 17.52% | -0.28 pp |
| Public | 16.32% | 16.36% | 16.62% | 16.93% | +0.31 pp |
Filed with NSE for Sept 2026: promoters 63.92%, public 36.08%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 12.83% (+0.15 pp)- Promoters63.9%
- Foreign institutions1.6%
- Mutual funds12.8%
- Insurance4.7%
- Other domestic institutions0.0%
- Retail11.7%
- Others5.2%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Quant Small Cap Fund | 3.44% | 1.77% | +0.48 pp |
| Nippon India Small Cap Fund | 2.55% | 0.58% | -0.16 pp |
| ICICI Pru Healthcare Fund | 0.95% | 2.33% | +0.36 pp |
| Nippon India Multi Cap Fund | 0.77% | 0.25% | -0.06 pp |
| ICICI Pru Small Cap Fund | 0.75% | 1.44% | -0.36 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 24.0%
- Downside volatility
- 22.6%
- Worst 5% of days
- 2.5%
- Average of that tail
- 3.3%
- Max drawdown (1Y)
- 34.7%
- Below its peak
- 30.5%
Against the market
- Beta vs Nifty 50
- 0.62
- Correlation
- 0.35
- Relative strength (3M)
- -24.3%
- ATR (14)
- 2.5%
Return
- Return 1M
- +0.7%
- Return 3M
- -20.4%
- Return 6M
- -20.9%
- Return 1Y
- -25.3%
- vs 200-day average
- -15.3%
Momentum
- RSI (14)
- 49.0
- MACD histogram
- 19.76
- Stochastic %K
- 65.2
- ADX (14)
- 19.2
- +DI / −DI
- 19.6 / 21.6
- Money flow index
- 70.4
Participation
- Delivery (20d avg)
- 50.7%
- vs its 60-day baseline
- -2.6 pts
- Volume vs 20-day
- -0.4σ
- Close vs day's VWAP
- +0.3%
- 52-week position
- 12 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
3 of 5 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — not testableneeds total income and expenses a year apart
- Asset turnover improving — failed
- Free cash flow
- ₹942 Cr
- FCF yield
- 5.4%
- Net debt
- ₹104 Cr
- Net debt / equity
- 0.02
- PEG
- 0.35
- Revenue CAGR
- 13.2%
- Profit CAGR
- 65.7%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹75.00
Dividend - Rs 75 Per Share
17 Jul 2026ex-date - dividend₹35.00
Dividend - Rs 35 Per Share & Special Dividend Of Rs 100 Per Share/ Special Dividend Of Rs 30
9 Jul 2025ex-date - dividend₹35.00
Dividend - Rs 35 Per Share
21 Aug 2024ex-date - dividend₹35.00
Dividend - Rs 35 Per Share/ Special Dividend - Rs 5 Per Share
11 Aug 2023ex-date - dividend₹30.00
Special Dividend - Rs 30 Per Share
19 Sept 2022ex-date - dividend₹35.00
Dividend - Rs 35 Per Share
18 Aug 2022ex-date - dividend₹30.00
Annual General Meeting/Dividend - Rs 30 Per Share/Special Dividend - Rs 5 Per Share
11 Aug 2021ex-date - dividend₹10.00
Annual General Meeting/Dividend - Rs 10 Per Share
27 Aug 2020ex-date - dividend₹320.00
Special Dividend - Rs 320 Per Share
6 May 2020ex-date - dividend₹22.50
Dividend - Rs 22.50 Per Share
1 Aug 2019ex-date - dividend₹20.00
Annual General Meeting/Dividend- Rs 20 Per Share
29 Aug 2018ex-date - dividend₹15.00
Dividend Rs 15/- Per Share + Special Dividend Rs 5/- Per Share
22 Aug 2017ex-date - dividend₹15.00
Dividend - Rs.15/- Per Share
27 Jun 2016ex-date - dividend₹12.50
Annual General Meeting And Dividend Rs.12.50 Per Share
3 Jul 2015ex-date - otherNot available — not reported in this filing
Annual General Meeting
29 Oct 2014ex-date - dividend₹360.00
Interim Dividend - Rs 360/- Per Share
5 Dec 2013ex-date - dividend₹12.50
Annual General Meeting / Dividend - Rs 12.50/- Per Share + Special Dividend - Rs 20/- Per Share
28 Aug 2013ex-date - dividend₹12.50
Annual General Meeting/ Dividend Rs 12.50 Per Share
24 Jul 2012ex-date - dividend₹4.00
Dividend-Rs.4/- Per Share
8 Jul 2011ex-date - dividend₹12.50
Interim Dividend-Rs.12.50 Per Share
20 Jan 2011ex-date
Company announcements
Please find attached Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Please find enclosed copy of newspaper advertisements for Transfer and Dematerialisation of Physical Securities.
Intimation for Closure of Trading Window.
Intimation for order issued by the Deputy/Additional Commissioner of Income Tax Transfer Pricing.
Intimation regarding change in Senior Management Personnel of the Company.
Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026.
Newspaper Advertisement - Special Window for Re- lodgement of Transfer and Dematerialisation of Physical Securities.
Pursuant to Regulation 44 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, we submit herewith the consolidated Scrutinizer's Report of the votes cast through ....
Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, please find enclosed proceedings of the 75th Annual General Meeting of the Company held on July 28, 2026.
Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for ....
Intimation of Resignation of Mr. Amit Agarwal, Executive Director -Finance & Chief Financial Officer
Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve This is to inform that a meeting of ....
Response to clarification sought with reference to news item appearing in 'The Hindu BusinessLine'
The Exchange has sought clarification from Pfizer Ltd on July 17, 2026, with reference to news appeared in https://www.thehindubusinessline.com/ dated July 17, 2026 quoting "Pfizer suspends ....
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026
Filed with BSE (scrip 500680); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Open offer
Pfizer Limited
21 Apr 2009Read on SEBI
Regulatory orders
- Order
Consent Order in the matter of Pfizer Limited
22 Feb 2010Read on SEBI
Documents
Annual reports
Earnings calls
- Aug 2020Transcript
- May 2017Transcript
- Feb 2017Transcript
- Nov 2016Transcript
- Aug 2016Transcript
- May 2016Transcript
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Pfizer: common questions
Answered from the figures on this page.